Inclusion Criteria:

1. Subjects must have a histologically confirmed diagnosis of glioblastoma multiforme or
gliosarcoma;

2. Measurable disease by RANO criteria;

3. Disease progression or recurrence following standard of care treatment with
temozolomide and radiation;

4. An interval of at least 4 weeks between prior surgical resection and study
enrollment;

5. An interval of at least 12 weeks between prior radiotherapy or at least 4 weeks from
prior chemotherapy, and enrollment in this protocol;

6. Recovered to Grade 1 or less from the toxic effects of any earlier intervention;

7. Karnofsky performance status > 60%

Exclusion Criteria:

1. Prior anti-angiogenic therapy including VEGF sequestering agents (ie bevacizumab,
aflibercept, etc) or VEGFR inhibitors (cedirinib, pazopanib, sunitinib, sorafenib,
etc);

2. Prior stereotactic radiotherapy;

3. Active infection;

4. Evidence of CNS haemorrhage CTCAE grade 2 or above on baseline MRI;

5. Requires therapeutic anti-coagulation;

6. Subjects who suffered from an acute cardiac event within the last 12 months;

7. Subjects with active vascular disease, either myocardial or peripheral;

8. Subjects with proliferative and/or vascular retinopathy;

9. Subjects with known active second malignancy;